Stockreport
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
TheFly reported on March 16 that Wells Fargo maintained an Overweight rating on BMRN with a $75 price target. The firm noted that BioMarin discontinued three Phase 2 Voxzogo studies in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency due to cases of Slipped Capital Femoral Epiphysis observed in investigator-sponsored trials. Wells Fargo views the safety risk as specific to certain indications rather than the drug's mechanism, and considers BMRN's outlook less dependent on Voxzogo. The firm indicated it remains supportive and sees the shares as a buying opportunity in the event of price weakness. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported positive new results from ongoing clinical trials and real-world studies of Voxzogo (vosoritide) in children with achondroplasia. The findings highlight the benefits of early treatment, demonstrating sustained multi-year growth improvements, enhanced body proportionality, and increased arm span compared to untreated child
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (BMRN) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".[MarketBeat]
- BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha][Seeking Alpha]
- BioMarin Pharmaceutical (BMRN) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".[MarketBeat]
- Here is Why BioMarin (BMRN) is Projected to Rally [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (BMRN) was upgraded by Truist Financial Corporation to "strong-buy".[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- BMRN's page on the SEC website
- More